1. Home
  2. ICE vs GKOS Comparison

ICE vs GKOS Comparison

Compare ICE & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intercontinental Exchange Inc.

ICE

Intercontinental Exchange Inc.

N/A

Current Price

$157.12

Market Cap

93.2B

Sector

Finance

ML Signal

N/A

Logo Glaukos Corporation

GKOS

Glaukos Corporation

N/A

Current Price

$107.57

Market Cap

6.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ICE
GKOS
Founded
2000
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
93.2B
6.0B
IPO Year
2013
2015

Fundamental Metrics

Financial Performance
Metric
ICE
GKOS
Price
$157.12
$107.57
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
14
Target Price
$196.44
$133.07
AVG Volume (30 Days)
2.8M
593.3K
Earning Date
04-30-2026
04-29-2026
Dividend Yield
1.32%
N/A
EPS Growth
20.71
N/A
EPS
5.77
N/A
Revenue
$5,834,000,000.00
$507,442,000.00
Revenue This Year
$8.53
$23.34
Revenue Next Year
$5.55
$27.46
P/E Ratio
$27.16
N/A
Revenue Growth
N/A
32.33
52 Week Low
$143.17
$73.16
52 Week High
$189.35
$130.23

Technical Indicators

Market Signals
Indicator
ICE
GKOS
Relative Strength Index (RSI) 45.15 50.69
Support Level $152.08 $104.72
Resistance Level $162.48 $113.50
Average True Range (ATR) 2.80 3.86
MACD -0.11 0.86
Stochastic Oscillator 39.75 84.99

Price Performance

Historical Comparison
ICE
GKOS

About ICE Intercontinental Exchange Inc.

Intercontinental Exchange is a vertically integrated operator of financial exchanges and provides ancillary data products. Though the company is probably best known for its ownership of the New York Stock Exchange, which it acquired in 2013, ICE operates a large derivatives exchange, too. The company's largest commodity futures product is the ICE Brent crude futures contract. In addition to the exchanges business, which is about 54% of net revenue, Intercontinental Exchange has used a series of acquisitions to create its mortgage technology business (22% of net revenue) and fixed-income and data services segment (24% of net revenue).

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: